China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $4.61M
• Dividend Yield: N/A
• Average Volume (3M): 614.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: -35.41%
• EPS Growth: 72.85%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 74
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 32,619,110
• 10 Day Avg. Volume: 504,579
• 30 Day Avg. Volume: 614,644
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.82
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.78
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -29.17
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

China Pharma Holdings' overall stock score is low due to significant financial challenges, including consistent losses and high debt levels. Technical analysis suggests some short-term momentum, but this is offset by a negative MACD and potential overbought conditions. The valuation is further weakened by a negative P/E ratio and lack of dividends. Financial health improvements are critical for future stock performance.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the production and sale of pharmaceutical products. The company's revenue model is based on the commercialization of its diverse portfolio of drugs, which includes both prescription and over-the-counter medications. Key revenue streams include sales to hospitals, pharmacies, and other healthcare institutions. Additionally, China Pharma Holdings may engage in strategic partnerships with other pharmaceutical companies to expand its product offerings and market reach, thereby enhancing its revenue potential. The company's earnings are influenced by factors such as product pricing, market demand, regulatory approvals, and its ability to innovate and introduce new products to the market.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces significant financial challenges, characterized by declining revenue, persistent losses, and negative cash flows. High leverage and decreasing shareholder equity add to the financial instability. The company must address its cost structure and improve cash flow management to stabilize its financial position.

Income Statement

The company has been consistently operating at a loss, with negative gross profit, EBIT, and net income in recent periods. Revenue has been declining from 2020 to the TTM (Trailing-Twelve-Months) period. The gross profit margin is negative due to higher costs relative to revenue, and there is a consistent decline in EBIT and EBITDA margins.

Balance Sheet

The debt-to-equity ratio is concerning, indicating high leverage, though it has improved slightly in the TTM period. The equity ratio is relatively stable, but the company's declining equity position and high total liabilities pose financial risks. ROE is negative, reflecting operating losses.

Cash Flow

Operating and free cash flows are negative, indicating cash burn. The cash flow to net income ratios are not favorable, further highlighting financial strains. Free cash flow has been declining, suggesting challenges in generating cash.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
7.01M	8.10M	9.64M	10.87M	10.92M
	Gross Profit
-281.08K	-493.92K	349.27K	1.95M	1.48M
	EBIT
-2.75M	-3.55M	-3.12M	-2.46M	-3.39M
	EBITDA
8.44K	-837.69K	230.34K	106.85K	-17.45M
	Net Income Common Stockholders
-3.08M	-10.22M	-3.94M	-3.16M	-21.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.42M	2.03M	4.86M	957.65K	1.07M
	Total Assets
16.47M	17.78M	22.65M	21.12M	22.24M
	Total Debt
4.63M	8.76M	12.49M	7.43M	4.55M
	Net Debt
3.21M	6.73M	7.63M	6.47M	3.48M
	Total Liabilities
9.01M	13.49M	16.63M	13.11M	13.00M
	Stockholders Equity
7.45M	4.29M	6.02M	8.00M	9.24M
Cash Flow		Free Cash Flow
-711.20K	-811.51K	-687.89K	-909.57K	472.31K
	Operating Cash Flow
-699.69K	-409.55K	-249.84K	-42.26K	608.31K
	Investing Cash Flow
-11.52K	-401.96K	-438.06K	-867.31K	-136.00K
	Financing Cash Flow
73.14K	-1.77M	4.60M	624.18K	-1.73M

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Neutral. The current price of 2.15 is above the 20-day moving average (MA) of 1.68, above the 50-day MA of 2.13, and above the 200-day MA of 2.15, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 52.36 is Neutral, neither overbought nor oversold. The STOCH value of 76.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
XBIO	43 Neutral	$4.38M	―	-50.12%	―	-1.56%	5.01%
SBFM	40 Underperform	$5.13M	―	-22.97%	―	44.75%	86.42%
CPHI	35 Underperform	$4.61M	―	-61.58%	―	-35.41%	72.85%

China Pharma Holdings Corporate Events

China Pharma Holdings Announces Reverse Stock Split

On April 4, 2025, China Pharma Holdings announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This move, authorized by the Board and stockholders, will consolidate every 10 shares into one, affecting all shareholders uniformly without altering their percentage interest in the company.